Dr Louise Hiller

Job Title

Associate Professor (Research Focussed)

Department

WMS - Warwick Clinical Trials Unit

Phone

02476150179

L.Hiller@warwick.ac.uk

Research Interests

I work predominately on randomised Phase II and III Breast Cancer Clinical Trials, analysing the clinical data from these as well as their Proteomics and Genomics sub-studies. I have previously researched into outcome measures in Obstetrics and Gynaecology, writing a PhD on the Evaluation of the Statistical Validation of Questionnaires for use as Outcome Measures in Clinical Trials.

Azam, Ayesha S., Tsang, Yee?Wah, Thirlwall, Jenny, Kimani, Peter K., Sah, Shatrughan, Gopalakrishnan, Kishore, Boyd, Clinton, Loughrey, Maurice B., Kelly, Paul J., Boyle, David P., Salto?Tellez, Manuel, Clark, David, Ellis, Ian O., Ilyas, Mohammad, Rakha, Emad, Bickers, Adam, Roberts, Ian S. D., Soares, Maria F., Neil, Desley A. H., Takyi, Abi et al (Select to open full list), 2024. Digital pathology for reporting histopathology samples, including cancer screening samples ? definitive evidence from a multisite study. Histopathology
Quenby, Siobhan, Booth, Katie, Hiller, Louise, Coomarasamy, Arri, de Jong, Paulien G., Hamulyák, Eva N., Scheres, Luuk J., van Haaps, Thijs F., Ewington, Lauren J., Tewary, Shreeya, Goddijn, Mariëtte, Middeldorp, Saskia, 2023. Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2) : an international open-label, randomised controlled trial. Lancet, 402 (10395), pp. 54-61
'Yao, C., 'Osdoit, M., 'van der Noordaa, M., 'Shad, S., 'Wei, J., 'de Croze, D., 'Hamy, A -S., 'La?, M., 'Reyal, F., 'Sonke, G. S., 'Steenbruggen, T. G., 'van Seijen, M., 'Wesseling, J., 'Mart?n, M., 'del Monte-Mill?n, M., 'L?pez-Tarruella, S., 'Boughey, J. C., 'Goetz, M. P., 'Hoskin, T., 'Gould, R. et al (Select to open full list), 2022. 'Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients. Lancet Oncology, 23 (1), pp. 149-160
'Sudin, Ellhia, 'Searjeant, Mitchell, 'Partridge, George, 'Phillips, Peter W., 'Hiller, Louise, 'Snead, David R. J., 'Ellis, Ian O., 'Chen, Yan, 2022. 'Digital pathology : the effect of experience on visual search behavior. Journal of Medical Imaging, 9 (03)
Sammut, S., Crispin-Ortuzar, M., Chin, S. F., Provenzano, E., Bardwell, H. A., Ma, W., Cope, W., Dariush, A., Dawson, S. J., Abraham, J., Dunn, Janet A., Hiller, Louise, Thomas, J., Cameron, D. A., Bartlett, John M. S., Hayward, Larry, Pharoah, Paul D., Markowetz, Florian, Rueda, Oscar M., Earl, Helena M. et al (Select to open full list), 2022. Multi-omic machine learning predictor of breast cancer therapy response. Nature, 601, pp. 623-629
Earl, Helena M., Hiller, Louise, Dunn, Janet A., Macpherson, Iain, Rea, Daniel, Hughes-Davies, Luke, McAdam, Karen, Hall, Peter, Mansi, Janine, Wheatley, Duncan, Abraham, Jean, Caldas, Carlos, Gasson, Sophie, O'Riordan, Liz, Wilcox, Maggie, Miles, David, Cameron , David, Wardley, Andrew, 2021. Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology, 33 (1), pp. 15-19
Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mahler-Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Gasson, Sophie, Balmer, Claire E., Abraham, Jean E., Caldas, Carlos, Hall, Peter et al (Select to open full list), 2020. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 24 (40), pp. 1-190
Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis et al (Select to open full list), 2019. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet, 393 (10191), pp. 2599-2612
Escala-Garcia, Maria, Guo, Qi, Dörk, Thilo, Canisius, Sander, Keeman, Renske, Dennis, Joe, Beesley, Jonathan, Lecarpentier, Julie, Bolla, Manjeet K., Wang, Qin, Abraham, Jean, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L., Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bernstein, Leslie et al (Select to open full list), 2019. Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 120 (6), pp. 647-657
Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M., Earl, Helena M., 2018. Adjuvant trastuzumab duration trials in HER2 positive breast cancer : what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer, 18
Guo, Qi, Burgess, Stephen, Turman, Constance, Bolla, Manjeet K., Wang, Qin, Lush, Michael, Abraham, Jean, Aittomäki, Kristiina, Andrulis, Irene L, Apicella, Carmel, Arndt, Volker, Barrdahl, Myrto, Benitez, Javier, Berg, Christine D., Blomqvist, Carl, Bojesen, Stig E, Bonanni, Bernardo, Brand, Judith S, Brenner, Hermann, Broeks, Annegien et al (Select to open full list), 2017. Body mass index and breast cancer survival : a Mendelian randomization analysis. International Journal of Epidemiology, 46 (6), pp. 1814-1822
Earl, H. M., Hiller, Louise, Dunn, Janet A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Gounaris, I., Abraham, J. E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J. M. S., Cameron, D. A., Provenzano, E., Thomas, J., Hayward, R. L., 2017. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer : ARTemis Trial. Annals of Oncology, 28 (8), pp. 1817-1824
Ali, H. R., Dariush, A., Thomas, J., Provenzano, E., Dunn, Janet A., Hiller, Louise, Vallier, A.-L., Abraham, J., Piper, T., Bartlett, J. M. S., Cameron, D. A., Hayward, L., Brenton, J. D., Pharoah, P. D. P., Irwin, M. J., Walton, N. A., Earl, H. M., Caldas, C., 2017. Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer : secondary analysis of the ARTemis trial. Annals of Oncology, 28 (8), pp. 1832-1835
Thomas, Jeremy St John, Provenzano, Elena, Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Gounaris, Ioannis, Abraham, Jean, Hughes-Davies, Luke, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Caldas, Carlos, Bartlett, John M. S., Cameron, David Allan, Hayward, Richard Laurence et al (Select to open full list), 2017. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. Modern Pathology, 30 (8), pp. 1069-1077
Earl, Helena M., Hiller, Louise, Howard, Helen C., Dunn, Janet A., Young, Jennie, Bowden, Sarah J., McDermaid, Michelle, Waterhouse, Anna K., Wilson, Gregory, Agrawal, Rajiv, O'Reilly, Susan, Bowman, Angela, Ritchie, Diana M., Goodman, Andrew, Hickish, Tamas, McAdam, Karen, Cameron, David, Dodwell, David, Rea, Daniel W., Caldas, Carlos et al (Select to open full list), 2017. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo) : final 10-year follow-up of an open-label, randomised, phase 3 trial. The Lancet Oncology, 18 (6), pp. 755-769
Dorling, L, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
Earl, Helena M, Vallier, Anne-Laure, Dunn, Janet A., Loi, Shrushma, Ogburn, Emma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian, Abraham, Jean, Wardley, Andrew, Cameron, David A, Miles, David, Gounaris, Ioannis, Plummer, Chris, Hiller, Louise, 2016. Trastuzumab-associated cardiac events in the Persephone trial. British Journal of Cancer, 115 (12), pp. 1462-1470
Ali, H. Raza, Dariush, Aliakbar, Provenzano, Elena, Bardwell, Helen, Abraham, Jean E., Iddawela, Mahesh, Vallier, Anne-Laure, Hiller, Louise, Dunn, Janet A., Bowden, Sarah J., Hickish, Tamas, McAdam, Karen, Houston, Stephen, Irwin, Mike J., Pharoah, Paul D. P., Brenton, James D., Walton, Nicholas A., Earl, Helena M., Caldas, Carlos, 2016. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 18 (1)
Thamm, Douglas, Dorling, Leila, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancakova, A., Chen, Y., Varga, T. V., Yaghootkar, H., Luan, J., Zhao, J. H., Willems, S. M., Wessel, J., Wang, S., Maruthur, N., Michailidou, K., Pirie, A., van der Lee, S. J. et al (Select to open full list), 2016. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science Translational Medicine, 8 (341)
Abraham, Jean E., Hiller, Louise, Dorling, Leila, Vallier, Anne-Laure, Dunn, Janet A., Bowden, Sarah, Ingle, Susan, Jones, Linda, Hardy, Richard, Twelves, Christopher, Poole, Christopher J., Pharoah, Paul D. P., Caldas, Carlos, Earl, Helena M., 2015. A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Medicine, 13 (1)
Guo, Q., Schmidt, M. K., Kraft, P., Canisius, S., Chen, C., Khan, S., Tyrer, J., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Lush, M., Kar, S., Beesley, J., Dunning, A. M., Shah, M., Czene, K., Darabi, H., Eriksson, M., Lambrechts, D. et al (Select to open full list), 2015. Identification of Novel Genetic Markers of Breast Cancer Survival. JNCI Journal of the National Cancer Institute, 107 (5)
Earl, Helena M., Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Abraham, Jean, Thomas, Jeremy, Provenzano, Elena, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Bartlett, John, Caldas, Carlos, Cameron, David A et al (Select to open full list), 2015. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis) : an open-label, randomised, phase 3 trial. The Lancet Oncology, 16 (6), pp. 656-666
Ali, H. R., Glont, S.- E., Blows, F. M., Provenzano, E., Dawson, S.- J., Liu, B., Hiller, Louise, Dunn, Janet A., Poole, C. J., Bowden, S., Earl, H. M., Pharoah, P. D. P., Caldas, C., 2015. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology, 26 (7)
Pirie, Ailith, Guo, Qi, Kraft, Peter, Canisius, Sander, Eccles, Diana M, Rahman, Nazneen, Nevanlinna, Heli, Chen, Constance, Khan, Sofia, Tyrer, Jonathan, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Michailidou, Kyriaki, Lush, Michael, Dunning, Alison M, Shah, Mitul, Czene, Kamila, Darabi, Hatef, Eriksson, Mikael et al (Select to open full list), 2015. Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 17 (1)
Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon et al (Select to open full list), 2014. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. The Lancet Oncology, Volulme 15 (2), pp. 201-212
Abraham, J. E., Guo, Q., Dorling, L., Tyrer, J., Ingle, S., Hardy, R., Vallier, A.-L., Hiller, Louise, Burns, R., Jones, L., Bowden, S. J., Dunn, Janet A., Poole, C. J., Caldas, C., Pharoah, P. P. D., Earl, Helena M., 2014. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clinical Cancer Research, 20 (9), pp. 2466-2475
Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon et al (Select to open full list), 2014. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo) : an open-label, 2×2 factorial randomised phase 3 trial. The Lancet Oncology, 15 (2), pp. 201-212
Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P. et al (Select to open full list), 2014. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Annals of Oncology, 25 (8), pp. 1536-1543
Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P. et al (Select to open full list), 2014. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Annals of Oncology, 25 (8), pp. 1536-1543
Ali, Alaa M., Provenzano, E., Barlett, J. M., Abraham, J., Driver, Kristy, Twelves, Chris, Munro, Alison F., Poole, Christopher, Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul, 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic subtypes in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
Ali, Alaa M., Provenzano, Elena, Bartlett, John M. S., Abraham, Jean, Driver, Kristy, Munro, Alison F., Twelves, Chris, Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul D., 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
Provenzano, E., Vallier, A. -L., Champ, R., Walland, K., Bowden, S. (Sarah), Grier, Anna, Fenwick, Nicola, Abraham, J. (Janet), Iddawela, M., Caldas, C., Hiller, Louise, Dunn, Janet A., Earl, Helena M., 2013. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. British Journal of Cancer, 108 (4), pp. 866-872
Earl, Helena M., Hiller, Louise, Dunn, Janet A., Vallier, A. -L., Bowden, S. J., Jordan, S. D., Blows, F., Munro, A., Bathers, S., Grieve, R., Spooner, David A., Agrawal, R., Fernando, I., Brunt, A. M., O'Reilly, S. M., Crawford, S. Michael, Rea, D. W., Simmonds, P., Mansi, J. L., Stanley, A. et al (Select to open full list), 2012. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, Vol.107 (No.8), pp. 1257-1267
Campbell, H. E., Epstein, D., Bloomfield, D., Griffin, S., Manca, A., Yarnold, J., Bliss, J., Johnson, L., Earl, Helena M., Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Hopwood, P., Barrett-Lee, P., Ellis, P., Cameron, D., Harris, A. L., Gray, A. M., Sculpher, Mark J., 2011. The cost-effectiveness of adjuvant chemotherapy for early breast cancer : a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer, Vol.47 (No.17), pp. 2517-2530
Hiller, Louise, Dunn, Janet A., Higgins, Helen B., Ogburn-Storey, Emma, Loi, Shrushma, Vallier, Anne-Laure, Earl, Helena M., 2011. Optimising patient recall of adverse events over prolonged time periods. Trials, Vol.12 (Suppl.1)
Gounaris, I., Provenzano, E., Vallier, A. L., Hiller, Louise, Iddawela, M., Hilborne, S., Taylor, K. (Kathryn), Britton, Peter, Earl, Helena M., Sinnatamby, R., 2011. Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment, 127 (2), pp. 459-469
Hannigan, Adèle, Smith, Paul J., Kalna, Gabriela, Lo Nigro, Cristiana, Orange, Clare, O'Brien, Darren I., Shah, Reshma, Syed, Nelofer, Spender, Lindsay C., Herrera, Blanca, Thurlow, Johanna K., Lattanzio, Laura, Monteverde, Martino, Maurer, Meghan E., Buffa, Francesca M., Mann, Jelena, Chu, David C. K., West, Catharine M. L., Patridge, Max, Oien, Karin A. et al (Select to open full list), 2010. Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. Journal of Clinical Investigation, Vol.120 (No.8), pp. 2842-2857
Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M., Poole, Christopher, 2010. Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3), pp. 266-274
Nicholson, Linda J., Smith, Paul R., Hiller, Louise, Szlosarek, Peter W., Kimberley, Christopher, Sehouli, Jalid, Koensgen, Dominique, Mustea, Alexander, Schmid, Peter, Crook, Tim, 2009. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. International Journal of Cancer, Vol.125 (No.6), pp. 1454-1463
Pepper, Chris, Lin, Thet Thet, Pratt, Guy, Hewamana, Saman, Brennan, Paul, Hiller, Louise, Hills, R., Ward, Rachel, Starczynski, Jane, Austen, Belinda, Hooper, Laura, Stankovic, Tatjana, Fegan, Chris, 2008. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood, Vol.112 (No.9), pp. 3807-3817
Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, David A., Poole, Christopher, 2008. NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8), pp. 1226-1231
Wardley, A. M., Hiller, Louise, Howard, H. C., Dunn, Janet A., Bowman, A., Coleman, R. E., Fernando, I. N., Ritchie, D. M., Earl, Helena M., Poole, Christopher J., 2008. tAnGo : a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer : a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer, Vol.99 (No.4), pp. 597-603
Smith, Paul, Nicholson, Linda J., Syed, Nelofer, Payne, Annette, Hiller, Louise, Garrone, Ornella, Occelli, Marcella, Gasco, Milena, Crook, Tim, 2007. Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clinical Cancer Research, Vol.13 (No.14), pp. 4061-4068
Ainsworth, R., Dziedzic, K., Hiller, Louise, Daniels, J., Bruton, A., Broadfield, J., 2007. A prospective double blind placebo-controlled randomized trial of ultrasound in the physiotherapy treatment of shoulder pain. Rheumatology, Vol.46 (No.5), pp. 815-820
Donnelly, P., Hiller, Louise, Bathers, S., Bowden, S., Coleman, R., 2007. Questioning specialists' attitudes to breast cancer follow-up in primary care. Annals of Oncology, 18 (9), pp. 1467-1476
Tennant, Ruth, Hiller, Louise, Fishwick, Ruth, Platt, Stephen, Joseph, Stephen, Weich, Scott, Parkinson, Jane, Secker, Jenny, Stewart-Brown, Sarah L., 2007. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS) : development and UK validation. Health and Quality of Life Outcomes, Vol.5 (No.63)
Piper, M. K., Raza, K., Nuttall, S. L., Stevens, R., Toescu, V., Heaton, S., Gardner-Medwin, J., Hiller, Louise, Martin, U., Townend, J., Bacon, P. A., Gordon, Caroline, 2007. Impaired endothelial function in systemic lupus erythematosus. Lupus, Vol.16 (No.2), pp. 84-88
Hiller, Louise, Bradshaw, H. D., Radley, S. C., Radley, S., 2007. Criterion validity of the BBUSQ-22: a questionnaire assessing bowel and urinary tract symptoms in women. International Urogynecology Journal, Vol.18 (No.10), pp. 1133-1137
Poole, Christopher J., Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, Sarah, Grieve, Robert J., Spooner, David A., Agrawal, Rajiv K., Brunt, A. Murray, O'Reilly, Susan M., Crawford, S. Michael, Rea, Daniel W., Simmonds, Peter, Mansi, Janine L., Stanley, Andrew, Harvey, Peter, McAdam, Karen, Foster, Liz, Leonard, Robert C. F., Twelves, Chris, 2006. Epirubicin and cyclophosphamide, methotrexate,and fluorouracil as adjuvant therapy for early breast cancer. New England Journal of Medicine, Vol.355 (No.18), pp. 1851-1862
Pemberton, N. C., Paneesha, S., Hiller, Louise, Starczynski, J., Hooper, L., Pepper, C., Pratt, G., Fegan, C., 2006. The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia. Leukemia & Lymphoma, 47 (7), pp. 1239-1244
Sullivan, Alexandra, Syed, Nelofer, Gasco, Milena, Bergamaschi, Daniele, Trigiante, Giuseppe, Attard, Marlene, Hiller, Louise, Farrell, Paul J, Smith, Paul, Lu, Xin, Crook, Tim, 2004. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene, 23 (19), pp. 3328-3337
Hussain, S. A., Palmer, D. H., Ganesan, R., Hiller, Louise, Gregory, J., Murray, P. G., Pastorek, J., Young, L., James, N. D., 2004. Carbonic anhydrase IX, a marker of hypoxia : correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncology Reports, 11 (5), pp. 1005-1010
Hussain, S. A., Ganesan, R., Hiller, Louise, Murray, P. G., El-Magraby, M. M., Young, L., James, N. D., 2003. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. British Journal of Cancer, 88 (4), pp. 586-592
Hussain, S. A., Ganesan, R., Hiller, Louise, Cooke, P. W., Murray, P., Young, L. S., James, N. D., 2003. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncology Reports, 10 (3), pp. 571-576
Hiller, Louise, Bradshaw, H. D., Radley, S. C., Radley, S., 2003. A scoring system for the assessment of bowel and lower urinary tract symptoms in women. BJOG: An International Journal of Obstetrics and Gynaecology, 109 (4), pp. 424-430
Wilson, D., Hiller, Louise, Gray, L., Grainger, M., Stirling, A., James, N., 2003. The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clinical Oncology, 15 (7), pp. 400-407
Bergamaschi, Daniele, Gasco, Milena, Hiller, Louise, Sullivan, Alexandra, Syed, Nelofer, Trigiante, Giuseppe, Yulug, Isik, Merlano, Marco, Numico, Gianmauro, Comino, Alberto, Attard, Marlene, Reelfs, Olivier, Gusterson, Barry, Bell, Alexandra K., Heath, Victoria, Tavassoli, Mahvash, Farrell, Paul J, Smith, Paul, Lu, Xin, Crook, Tim, 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3 (4), pp. 387-402
Batta, Kapila, Goodyear, Helen M., Moss, Celia, Williams, Hywel C., Hiller, Louise, Waters, Ruth, 2002. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas : results of a 1-year analysis. The Lancet, 360 (9332), pp. 521-527
Gasco, M., Bell, A. K., Heath, V., Sullivan, A., Smith, P., Hiller, Louise, Yulug, I., Numico, G., Merlano, M., Farrell, P. J., Tavassoli, M., Gusterson, B., Crook, T., 2002. Epigenetic inactivation of 14-3-3 s in oral carcinoma : association with p16INK4a silencing and human papillomavirus negativity. Cancer Research, 62 (7), pp. 2072-2076
Hiller, Louise, Radley, S., Mann, C. H., Radley, S. C., Begum, G., Pretlove, S .J., Salaman, J. H., 2002. Development and validation of a questionnaire for the assessment of bowel and lower urinary tract symptoms in women. BJOG: An International Journal of Obstetrics and Gynaecology, 109 (4), pp. 413-423
Eggar, Richard, Spencer, Amanda, Anderson, David, Hiller, Louise, 2002. Views of elderly patients on cardiopulmonary resuscitation before and after treatment for depression. International Journal of Geriatric Psychiatry, 17 (2), pp. 170-174
Demain, Sara, Smith, Jan Fereday, Hiller, Louise, Dziedzic, Krysia, 2001. Comparison of group and individual physiotherapy for female urinary incontinence in primary care. Physiotherapy, 87 (5), pp. 235-242
Brooks, L. A., Tidy, J. A., Gusterson, B., Hiller, Louise, O'Nions, J., Gasco, M., Marin, M. C., Farrell, P. J., Kaelin, Jr., Crook, T., 2000. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Research, 60 (24), pp. 6875-6877
Darnton, S. J., Zgainski, B., Grenier, I., Allister, K., Hiller, Louise, McManus, K. G., Steyn, R. S., 1999. The use of an anabolic steroid (nandrolone decanoate) to improve nutritional status after esophageal resection for carcinoma. Diseases of the Esophagus, 12 (4), pp. 283-288
Nicholl, D. J., Bennett, P., Hiller, Louise, Bonifati, V., Vanacore, N., Fabbrini, G., Marconi, R., Colosimo, C., Lamberti, P., Stocchi, F., Bonuccelli, U., Vieregge, P., Ramsden, D. B., Meco, G., Williams, A. C., 1999. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. Neurology, 53 (7), pp. 1415-1421
Etherington, I. J., Luesley, D. M., Shafi, M. I., Dunn, Janet A., Hiller, Louise, Jordan, J. A., 1997. Observer variability among colposcopists from the West Midlands region. BJOG: An International Journal of Obstetrics and Gynaecology, 104 (12), pp. 1380-1384

Gounaris, I., Sinnatamby, R., Taylor, K., Wallis, M., Hiller, Louise, Vallier, A.-L., Provenzano, E., Iddawela, M., Wishart, G., Earl, Helena M., Britton, P., 2010. O-31 Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patient. 1st British Breast Cancer Research Conference, Nottingham, England, 15-17 Sep 2010, Published in European Journal of Cancer Supplements, pp. 12-12
Bartlett, J. M. S., Munro, A., Dunn, Janet A., Hiller, Louise, Jordan, S., Twelves, Chris, Cameron, D. A., Thomas, J., Campbell, F., Rea, D. W., Provenzano, E., Pharoah, P., Caldas, Carlos, Earl, Helena M., Poole, Christopher J., 2009. Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEA Tadjuvant breast cancer trial. 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008, Published in Cancer Research, pp. 74S-74S
Earl, Helena M., Vallier, A., Hiller, Louise, Fenwick, N., Iddawela, M., Hughes-Davies, Luke, Provenzano, E., McAdam, K., Hickish, T., Caldas, C., 2009. Neo-tAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel +/- gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). 45th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, MAY 29-JUN 02, 2009, Published in Journal of Clinical Oncology
Batta, K., Goodyear, H., Moss, C., Williams, Hywel, Hiller, Louise, Waters, Ruth A., 2008. Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5-year analysis. 88th Annual Meeting of the British-Association-of-Dermatologists, Liverpool, England, Jul 01-04, 2008, Published in British Journal of Dermatology
Bowden, S., Gross, L., Poole, C. J., Hiller, Louise, Agrawal, R. K., McAdam, K. F., Earl, Helena M., Anwar, S., Rea, Dean, 2007. NEAT-A: accelerated sequential epirubicin followed by higher dose 14 day CMF, using pegfilgrastim, is a feasible alternative for delivering dose dense E-CMF chemotherapy in early breast cancer. 14th European Cancer Conference (ECCO 14), Barcelona, Spain, SEP 23-27, 2007, Published in European Journal of Cancer Supplements, pp. 194-195
Hiller, Louise, Fenwick, N., Vallier, A. L., Dunn, Janet A., Hilborne, S., Jones, L., Abraham, J., Iddawela, M., Caldas, Carlos, Earl, Helena M., 2007. The challenges of using radiological 'tumour response' as an endpoint in Neo-tAnGo: a national neo-adjuvant chemotherapy breast cancer trial. 10th Nottingham International Breast Cancer Conference, Nottingham, England, September 18-20, 2007, Published in European Journal of Cancer Supplements, pp. 33-34
Poole, C. J., Hiller, Louise, Howard, H. C., Loi, Shrushma, Dunn, Janet A., Canney, P., Wardley, A. M., Crown, J. P., Coleman, R. E., Verrill, M. W., Ellis, P. A., Leonard, R. C., Spooner, David A., Earl, Helena M., 2006. Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer.. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, DEC 14-17, 2006, Published in BREAST CANCER RESEARCH AND TREATMENT, pp. S114-S114
Casson, Alan G, Darnton, S.Jane, Subramanian, Sujata, Hiller, Louise, 2002. What is the optimal distal resection margin for esophageal carcinoma?. Thirty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, 25-27 Jan 1999, Published in The Annals of Thoracic Surgery, pp. 205-209

Hiller, Louise, Loi, S., Vallier, A. L., Howe, Donna L., Bell, P., Carey, J., Manazar, Uzma, Cameron, D., Miles, D., Wardley, A., 2017. Measurement methods for eliciting opinions on treatment benefits, toxicities and acceptable trade-offs of the two, within the PERSEPHONE trial. Trials, Biomed Central Ltd
Mistry, Pankaj, Hiller, Louise, Iqbal, Gulnaz, Dunn, Janet A., 2015. Under-representation of male patients in breast cancer studies. Trials, Biomed Central Ltd
Hiller, Louise, Marshall, A. (Andrea)?, Dunn, Janet A., 2015. Assessing violations of the proportional hazards assumption in Cox regression : does the chosen method matter?. Trials, Biomed Central Ltd
Hiller, Louise, Vallier, A. L., Ogburn, E., Wardley, A. M., Cameron, D. A., Miles, D., Dunn, Janet A., Earl, H. M., 2014. Cardiology monitoring substudy in the PERSEPHONE trial : 6 versus 12 months of trastuzumab. Journal of Clinical Oncology, American Society of Clinical Oncology
Earl, H. M., Cameron, D. A., Miles, D., Wardley, A. M., Ogburn, E., Vallier, A. L., Loi, S., Higgins, H. B., Hiller, Louise, Dunn, Janet A., 2013. PERSEPHONE : duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer-six versus twelve months. Journal of Clinical Oncology, American Society of Clinical Oncology
Earl, H. M., Chin, S. F., Dunning, M., Iddawela, M., Rueda, O., Russell, R., Jones, L., Vallier, A. L., Hughes-Davies, L., Abraham, J., Chan, S., Skene, A., Benstead, K., Gallagher, C. J., Murray, N., Ritchie, D., Dunn, Janet A., Hiller, Louise, Provenzano, E., Caldas, C., 2013. Neo-tAnGo science : a translational study of PAM 50 sub-typing in sequential fresh tissue samples during neoadjuvant chemotherapy. Journal of Clinical Oncology, American Society of Clinical Oncology
Earl, H. M., Vallier, A. L., Ogburn-Storey, E., Cameron, D. A., Wardley, A. M., Miles, D., Loi, S., Hiller, Louise, Higgins, H. B., Dunn, Janet A., 2013. PERSEPHONE : duration of trastuzumab with chemotherapy in women with HER-2+ve early breast cancer. Cancer Research, American Association of Cancer Research
Wishart, G. C., Benson, J. R., Absar, M. S., Vallier, A. L., Hiller, Louise, Fenwick, N., Champ, R., Provenzano, E., Caldos, C., Earl, H. M., 2009. Sentinel lymph node biopsy (SLNB) prior to primary chemotherapy (PC) in breast cancer patients. Cancer Research, American Association of Cancer Research, pp. 334S-334S
Donnelly, Peter K., Hiller, Louise, Dunn, Janet A., 2008. Follow-up after breast cancer : national randomised controlled trial is needed. British Medical Journal, B M J Publishing Group, pp. 461-462
Donnelly, Peter K., Hiller, Louise, Dunn, Janet A., 2008. Need for the iBreast trial ? risk adjusted breast cancer follow-up trial. BMJ, BMJ Publishing Group Ltd
Ainsworth, R., Dziedzic, K., Hiller, Louise, Daniels, J., Bruton, A., Broadfield, J., 2007. Comment on : a prospective double blind placebo-controlled randomized trial of ultrasound in the physiotherapy treatment of shoulder pain : reply. Rheumatology, Oxford University Press, pp. 230-231
Wilson, D., Hiller, Louise, Geh, J. I., 2005. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clinical Oncology, Elsevier Science London, pp. 81-90
Wilson, D., Hiller, Louise, Geh, I., 2004. ECF in gastric cancer. Clinical Oncology, Elsevier Science London, pp. 381-382

Title	Funder	Award start	Award end
Sugammadex for preventIoN oF pOst-operative pulmoNary complIcAtions (SINFONIA)	National Institute for Health Research (NIHR DoH)	01 Jun 2022	01 Nov 2026
NIHR PGfAR via Newcastle: Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET)	National Institute for Health Research (DoH)	18 May 2020	17 May 2026
COBIx: Multi-site validation of automated AI tool for screening of large bowel endoscopic biopsy slides	National Institute for Health Research (NIHR DoH)	01 Apr 2023	31 Mar 2026
NIHR Programme Grant:Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET) Year 6 costs	National Institute for Health Research (DoH)	03 Feb 2020	02 Feb 2026
NIHR HTA Stage 2: Volatile vs Total intravenous Anaesthesia for major non-cardiac surgery ? a randomised controlled triaL (VITAL)	National Institute for Health Research (NIHR DoH)	01 Nov 2020	30 Apr 2025
NIHR HTA Costed Extenison: Digital Pathology_Linked to Main award on IDEATE 58038	National Institute for Health Research (NIHR DoH)	01 Nov 2021	30 Apr 2023
ALIFE 2 extension 2 - link to 61060	Amsterdam Universitair Medische Centra	01 Mar 2020	14 Aug 2022
ALIFE 2 extension 2 - link to 61060	National Institute for Health Research (NIHR DoH)	01 Mar 2020	14 Aug 2022
ALIFE 2 extension 2 - link to 61060	National Institute for Health Research (DoH)	01 Mar 2020	28 Feb 2022
NIHR HTA: Whole slide imaging in pathology	National Institute for Health Research (DoH)	01 Nov 2018	31 Oct 2021
ALIFE2-EXTENSION	National Institute for Health Research (DoH)	01 May 2018	29 Feb 2020
Persephone extension and supplement	National Institute for Health Research (DoH)	01 Jul 2016	30 Jun 2019
ARTemis: Avastin randomised trial with nEo-adjuvant cheMotherapy for patinets with early breat cancer : Analysis Extension	Cambridge University Hospitals NHS Foundation Trust	01 Jul 2011	31 Dec 2018
Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with early HER 2 negative breast cancer Artemis Year 9 Funding - staff - Late Phase Study	Cancer Research UK	01 May 2017	30 Apr 2018
ARTEMIS Pre-operative Avastin with neo-adjuvant chemotherapy Years 7,8 & 9 Support Funding	Cancer Research UK	01 May 2015	30 Apr 2018
Second Recosting for extension of the Persephone HTA Trial	National Institute for Health Research (DoH)	01 Jul 2013	30 Jun 2016
HTA FULL proposal: OPTIMA (Pilot Study)	National Institute for Health Research (DoH)	01 Sept 2012	31 Aug 2013
3 month extention of the Persephone HTA Trial	National Institute for Health Research (DoH)	01 Apr 2013	30 Jun 2013
Molecular profiling of post menopausal women with breast cancer on neoadjuvant exemestane or tamoxifen (MONET)	University of Cambridge	01 Apr 2007	31 Mar 2009
Warwick Edinburgh Mental Wellbeing Scale: Proposal for Validation of the Scale on Data Collected in the HEBS Population Survey in September 2006	NHS Health Scotland	01 Jan 2007	30 May 2007

WMS Warwick Medical School

Dr Louise Hiller

All authors for Digital pathology for reporting histopathology samples, including cancer screening samples ? definitive evidence from a multisite study

All authors for 'Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients

All authors for Multi-omic machine learning predictor of breast cancer therapy response

All authors for Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT

All authors for 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

All authors for Genome-wide association study of germline variants and breast cancer-specific mortality

All authors for Body mass index and breast cancer survival : a Mendelian randomization analysis

All authors for Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial

All authors for Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo) : final 10-year follow-up of an open-label, randomised, phase 3 trial

All authors for A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

All authors for Identification of Novel Genetic Markers of Breast Cancer Survival

All authors for Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis) : an open-label, randomised, phase 3 trial

All authors for Common germline polymorphisms associated with breast cancer-specific survival

All authors for Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

All authors for Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo) : an open-label, 2×2 factorial randomised phase 3 trial

All authors for Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

All authors for Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients

All authors for Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

All authors for Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter